Protagenic Therapeutics receives Nasdaq delisting notice for equity and filing non-compliance

Protagenic Therapeutics, Inc.new

Stockholders' equity fell below $2.5M minimum per Listing Rule 5550(b)(1) as of June 30, 2025.
Company also cited for delayed Form 10-Q for quarter ended September 30, 2025 (Rule 5250(c)(1)).
Will request hearing before Nasdaq Hearings Panel; automatic 15-day stay of suspension granted.
Common stock and warrants will continue trading on Nasdaq during automatic stay and any extended stay.
Company expects to file the overdue 10-Q imminently but no assurance Panel will grant relief.

item 3.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.